

Antimicrobials for Multi-drug Resistant Gram Negative Bacilli (MDR GNB) & Availability in AHS

Antimicrobial Agent ¹ vial size	Activity	AHS acute care hospital Formulary Status/ Availability/Cost (as of date approved)	Contact Information
Cefiderocol (Fetroja) 1 g	CRE CPE CRPA (incl. MBL) CRAB SM (as part of combination therapy)	SAP⁴ and STEDT⁵ Very laborious acquisition process and expensive: \$306 CAD/1g + ~ \$1,878 USD shipping	SAP requests are processed through Inceptua via Imap portal: https://inceptua.com . Pre-approval letter from Health Canada no longer required. Shionogi 1-800-849-9707 medinfo@shionogi.com
Ceftazidime- avibactam (Avycaz) 2.5 g	CRE Class A + D CPE CRPA (non- MBL)	SAP⁴ and STEDT⁵ Ceftazidime-avibactam: \$1679.70/box of 10 vials (can only order by box) Aztreonam (SAP ⁴) \$34.65/1g vial <i>NB: Aztreonam-avibactam approved in Europe. Could use aztreonam 2g IV q8h + ceftaz- avi 2.5g q8h (each over 3h given simultaneously via Y-site) to cover MBL-producing GNBs.</i>	AbbVie AbbVie Medical Information Tel: 1-844-241-5011 medicalquestions@abbvie.com
Ceftolozane- tazobactam (Zerbaxa) 1.5 g vials contain ceftolozane 1 g/ tazobactam 0.5 g	CRE (non- CPP) CRPA (non- CPP)	FRG \$142.80/1.5g	Merck
Fosfomycin IV (Ivozfo) 4 g	CRE* CPE* CRPA (incl. MBL)	NF – STEDT \$19/g * Fosfomycin IV should be used as part of combination therapy for Enterobacterales other than E.coli.	Verity Pharmaceuticals Contact: Summer Stewart, s.stewart@veritypharma.com
Imipenem- relebactam (Recarbrio) 1.25g vial contains imipenem 500mg/cilastatin 500mg/relebactam 250mg	CRE Class A + D CPE CRPA (non- MBL)	SAP⁴ and STEDT⁵ \$321 USD/1.25g	Merck 1-800-463-7251 regulatoryaffairs_canada@merck.com
Meropenem- vaborbactam (Vabomere)	CRE Class A CPE	Approved by Health Canada \$150/2g	Xediton Pharmaceuticals

Antimicrobials for MDR GNB & Availability in AHS | 2

2g			
Colistin 150 mg	CRE ² CPE ² CRPA CRAB	F \$13.54/150mg	FRESENIUS KABI
Sulbactam- durlobactam (Xacduro) 1 g-0.5 g x 2	CRAB	SAP⁴ and STEDT⁵ \$190 USD/vial <i>NB: Give in combination with meropenem or imipenem</i>	
Tigecycline (Tygacil) 50 mg	CRE ³ CPE ³ CRAB SM (as part of combination therapy)	FRG Restricted to Infectious Diseases \$55.20/50mg <i>NB: NOT recommended for bacteremia or urinary tract infections</i>	Pfizer

1. Susceptibility testing available for all these agents, except fosfomycin IV for non-*E. coli* Enterobacterales. Contact microbiology lab.
2. Intrinsic resistance of: *Proteus* species, *Providencia* species, *Morganella morganii*, *Serratia marcescens*
3. Intrinsic resistance of: *Proteus* species, *Providencia* species, *Morganella morganii*
4. Special Access Programme (SAP) contact information:
Website: <https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access/drugs.html>
Phone: (613) 941-2108 (Must press 0 to reach an on-call officer)
Fax: (613) 941-3194
E-mail: SAPdrugs@hc-sc.gc.ca
5. Short Term Exceptional Drug Therapy (STEDT) program for NF or SAP drugs where therapy \$1500 per course:
STEDT application: [Short Term Exceptional Drug Therapy \(STEDT\) | Insite \(albertahealthservices.ca\)](#)

CPE = carbapenemase-producing *Enterobacterales*

Class A CPE – includes KPC, GES, NMC, SME, IMI carbapenemases

Class D CPE – includes OXA carbapenemases

CPP = carbapenemase producer

CRAB = carbapenem-resistant *Acinetobacter baumannii*

CRE = carbapenem-resistant *Enterobacterales*

CRPA = carbapenem-resistant *Pseudomonas aeruginosa*

F = formulary

FRG = formulary, restricted with guidelines

MBL = metallo-β-lactamase

NF = non-formulary

SAP = Special Access Programme request

SM = *Stenotrophomonas maltophilia*

STEDT = Short Term Exceptional Drug Therapy request

Antimicrobials for MDR GNB & Availability in AHS | 3

Acknowledgments: Christine Ondro PharmD; Tanis Dingle MD; Susan Fryters BScPharm, ACPR

Reviewed by AHS Antimicrobial Stewardship Subcommittee, August 27, 2025

Approved by AHS Antimicrobial Stewardship Subcommittee, August 27, 2025

Last updated: August 2025